Panitumumab with trade name Vectibix, is an FDA-approved drug for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. It is a human monoclonal antibody. Panitumumab binds to the human EGF receptor (EGFR), preventing binding of activating ligands, such as the EGF and transforming growth factor-α.
Anti-Panitumumab Antibody (2E7), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Panitumumab.
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
ELISA detection: 0.005-1 µg/ml
ELISA blocking: 1-30 µg/ml
Synonyms Mouse monoclonal to Panitumumab/Vectibix
Description Panitumumab with trade name Vectibix, is an FDA-approved drug for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. It is a human monoclonal antibody. Panitumumab binds to the human EGF receptor (EGFR), preventing binding of activating ligands, such as the EGF and transforming growth factor-α. Anti-Panitumumab Antibody (2E7), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Panitumumab.
Host Species Mouse
Conjugation Unconjugated
Immunogen Panitumumab
Purification Protein A affinity column Clone 2E7
Properties
- Subclass IgG1,K Concentration 0.5 mg/ml, lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
- Reconstitution Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
- Specificity The product is specific for Panitumumab.
- Storage The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
- Note GenScript can customize this product per customer's request including product size, buffer components, etc.
Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
ELISA detection: 0.005-1 µg/mlELISA blocking: 1-30 µg/ml
Other applications: user-optimized